Search
Opium
go.drugbank.com/drugs/DB11130ApprovedIllicitThis plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits.
Antrafenine
go.drugbank.com/drugs/DB01419ApprovedAntrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.
Technetium Tc-99m exametazime
go.drugbank.com/drugs/DB09163ApprovedIt can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease.
Arginine
go.drugbank.com/drugs/DB00125ApprovedInvestigationalNutraceuticalAn essential amino acid that is physiologically active in the L-form.
Mixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITOTridihexethyl
go.drugbank.com/drugs/DB00505ApprovedWithdrawnTridihexethyl is an antimuscarinic, anticholinergic drug. Tridihexethyl is no longer available in the US market.
Ethylmorphine
go.drugbank.com/drugs/DB01466IllicitInvestigationalIt is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world.
Pyruvic acid
go.drugbank.com/drugs/DB00119ApprovedInvestigationalNutraceuticalAn intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures.
Etorphine
go.drugbank.com/drugs/DB01497ExperimentalIllicitVet approvedIn certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes. … Etorphine is only available to the patients under an official prescription. In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II.
Heterotheca inuloides flower
go.drugbank.com/drugs/DB14331ApprovedIt is not an approved drug.
Mixtures: Arnica De LA AbuelaZanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigational[A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]